October 6, 2026 · The Author

The Platform Didn't Change

Moderna's COVID-19 vaccine, built on messenger RNA (mRNA), went out under an FDA emergency authorization in December 2020 and received full approval on January 31, 2022. [1] Not every COVID vaccine used this technology; Johnson & Johnson's, authorized in February 2021, carried the instructions for the virus's spike protein on a modified adenovirus instead. [6] Behind it was public money: trade press reported that the federal biodefense agency BARDA committed about $955 million to its development and that the government agreed in August 2020 to buy 100 million doses for $1.5 billion. [2]

On August 5, 2025, the Department of Health and Human Services announced it was winding down BARDA's mRNA vaccine work: 22 projects worth nearly $500 million. Its secretary said "the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu." [3][4] Contracts were terminated or reduced, a Defense Department collaboration involving Moderna was restructured, and reporting at the time said final-stage contracts continued and other mRNA uses within HHS were unaffected. [3][4]

On August 19, 2026, Merck and Moderna announced that a Phase 3 trial of a personalized mRNA cancer therapy, given with Keytruda, had met its main goal. The trial enrolled 1,137 people with resected stage IIB to IV melanoma. The therapy cut recurrence or death compared with Keytruda alone, and it also met a key secondary goal on spread of the disease. The companies called it the first positive Phase 3 result for an mRNA-based cancer therapy and said the numbers will come at a medical conference. [5]

The claim of this piece is that the platform did not change between those dates; the decision about it did. A government can fund a technology in a crisis and withdraw that funding by policy, and the evidence about the technology keeps arriving on its own schedule. In my reading, the wind-down follows the change in administration and its posture toward vaccines more than any new evidence. HHS gives a different reason, and the timing alone does not prove either.

The cancer result is a separate question. A positive trial in melanoma says nothing about whether the respiratory vaccines protect, and HHS's statement about that is its own claim, on which I take no position. What the sequence shows is narrower: support is a decision by people, for a use, and it can be pointed elsewhere without the evidence for other uses changing.

In my own account, I received Moderna's vaccine in February 2021, under that emergency authorization. My vaccination card records the product and the date; readers cannot check the card themselves.

For an investor, a company that lives on government money carries two risks that are easy to confuse: whether the technology works, and whether the funder keeps saying yes. The second can change with every election cycle, whatever the first shows. Ask which use the evidence supports, who makes the next funding decision, and what a change in administration would do to it.

Related: What FDA Support Is, on why a designation supports the process and not the evidence; We could not get people to notice RNA and Forty-four years, on how the platform was built.

Sources

The HHS statement is HHS's own and is reported here through two trade outlets; I could not open the release itself. The BARDA and purchase figures come from trade press reports of the agreements. The trial's effect sizes and safety details were not released in the announcement. The reading that the wind-down follows the change in administration and its posture more than new evidence, and that support is a decision about a use that can be redirected without changing the evidence for other uses, is the author's interpretation; HHS gives a different reason, and the timing is circumstantial. This is not medical or investment advice.